Lazard hikes Novavax's PT; shares soar


Lazard ups its price target on Novavax (NVAX) to $11 from $4, saying its vaccine for respiratory syncytial virus (RSV) is its most under appreciated asset.

Novavax shares +16.7% to $2.93.

"Notwithstanding the clinical and commercial success (~$1B in 2012), Synagis' indicated use may be narrower than Novavax's vaccine," says Lazard. Synagis is made by MedImmune.

Respiratory syncytial virus is a common, seasonal, and easily spread virus, characterized by runny noses, coughing, sneezing and fever. However, it can lead to severe lung disease in infants.

From other sites
Comments (4)
  • jamaicanholiday
    , contributor
    Comments (59) | Send Message
     
    Interesting news today and well deserved attention! This could set a new floor for the stock and certainly a 52 week high today.
    15 Aug 2013, 08:14 AM Reply Like
  • stargazers
    , contributor
    Comments (19) | Send Message
     
    Boy! About time, an analyst woke up. Good news. May foster buyout. Who knows what that could be. Any guesses at this stage ?
    15 Aug 2013, 08:32 AM Reply Like
  • jamaicanholiday
    , contributor
    Comments (59) | Send Message
     
    my guess is that BARDA is consulting with the FDA regarding recent trial results for possible "fast track" on one of their vaccines. Also, on the call yesterday, CEO Stan Erck referenced for the first time, the potential for "licensing agreements".......
    15 Aug 2013, 08:54 AM Reply Like
  • Scrying Biotech
    , contributor
    Comments (2819) | Send Message
     
    Please Note: At Wedbush found here: http://bit.ly/15JsInP Stan mentioned that funding for influenza programs is paid for by BARDA "through licensure" meaning through market approval.
    15 Aug 2013, 12:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs